221 related articles for article (PubMed ID: 20425563)
1. Does antiretroviral therapy increase or decrease the risk of cardiovascular disease?
Fichtenbaum CJ
Curr HIV/AIDS Rep; 2010 May; 7(2):92-8. PubMed ID: 20425563
[TBL] [Abstract][Full Text] [Related]
2. Antiretroviral combination therapy for HIV infection.
Lewis DA
Dent Update; 2003 Jun; 30(5):242-7. PubMed ID: 12861761
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
4. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
5. Nucleoside reverse transcriptase inhibitors in combination therapy for HIV patients: systematic review and meta-analysis.
Chowers M; Gottesman BS; Leibovici L; Schapiro JM; Paul M
Eur J Clin Microbiol Infect Dis; 2010 Jul; 29(7):779-86. PubMed ID: 20449621
[TBL] [Abstract][Full Text] [Related]
6. Current treatment strategies, complications and considerations for the use of HIV antiretroviral therapy during pregnancy.
Senise JF; Castelo A; Martínez M
AIDS Rev; 2011; 13(4):198-213. PubMed ID: 21975356
[TBL] [Abstract][Full Text] [Related]
7. Special considerations regarding antiretroviral therapy and infection prophylaxis in the HIV-infected individual with cancer.
Sparano JA; Kalkut G
Cancer Treat Res; 2001; 104():347-66. PubMed ID: 11191134
[No Abstract] [Full Text] [Related]
8. [HIV infection, antiretroviral therapy, and endothelium].
Hürlimann D; Weber R; Enseleit F; Lüscher TF
Herz; 2005 Sep; 30(6):472-80. PubMed ID: 16170677
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis, antiretroviral therapy, and emergence of resistance to antiretroviral agents in HIV-2 infection: a review.
Hightower M; Kallas EG
Braz J Infect Dis; 2003 Feb; 7(1):7-15. PubMed ID: 12807687
[TBL] [Abstract][Full Text] [Related]
10. Nucleoside analogue-sparing strategy for the treatment of chronic HIV infection: potential interest and clinical experience.
Joly V; Yeni P
Antivir Ther; 2005; 10(1):29-40. PubMed ID: 15751761
[TBL] [Abstract][Full Text] [Related]
11. Nucleoside inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Sharma PL; Nurpeisov V; Hernandez-Santiago B; Beltran T; Schinazi RF
Curr Top Med Chem; 2004; 4(9):895-919. PubMed ID: 15134548
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of chronic treatment with the Main subclasses of highly active antiretroviral therapy: a systematic review.
Silva BF; Peixoto G; da Luz SR; de Moraes S; Peres SB
HIV Med; 2019 Aug; 20(7):429-438. PubMed ID: 31006976
[TBL] [Abstract][Full Text] [Related]
13. [Introduction. Cardiovascular disease and HIV infection].
Martínez E
Enferm Infecc Microbiol Clin; 2009 Sep; 27 Suppl 1():1-2. PubMed ID: 20213896
[No Abstract] [Full Text] [Related]
14. Non-nucleoside-reverse-transcriptase-inhibitor-based HAART and osteoporosis in HIV-infected subjects.
Bongiovanni M; Fausto A; Cicconi P; Aliprandi A; Cornalba G; Bini T; Sardanelli F; D'Arminio Monforte A
J Antimicrob Chemother; 2006 Aug; 58(2):485-6. PubMed ID: 16751202
[No Abstract] [Full Text] [Related]
15. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside or nucleotide-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw L; Mursleen S; Irlam JH; Spaulding AB; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD004246. PubMed ID: 27943261
[TBL] [Abstract][Full Text] [Related]
16. Cutaneous manifestations of antiretroviral therapy.
Ward HA; Russo GG; Shrum J
J Am Acad Dermatol; 2002 Feb; 46(2):284-93. PubMed ID: 11807442
[TBL] [Abstract][Full Text] [Related]
17. Separation methods for nucleoside analogues used for treatment of HIV-1 infection.
Pereira AS; Tidwell RR
J Chromatogr B Biomed Sci Appl; 2001 Nov; 764(1-2):327-47. PubMed ID: 11817036
[TBL] [Abstract][Full Text] [Related]
18. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction.
Francisci D; Giannini S; Baldelli F; Leone M; Belfiori B; Guglielmini G; Malincarne L; Gresele P
AIDS; 2009 Mar; 23(5):589-96. PubMed ID: 19177019
[TBL] [Abstract][Full Text] [Related]
19. Association of antiretroviral therapy with fibrinogen levels in HIV-infection.
Madden E; Lee G; Kotler DP; Wanke C; Lewis CE; Tracy R; Heymsfield S; Shlipak MG; Bacchetti P; Scherzer R; Grunfeld C
AIDS; 2008 Mar; 22(6):707-15. PubMed ID: 18356600
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of switching from protease inhibitors to dolutegravir in combination with nucleoside reverse transcriptase inhibitors as maintenance antiretroviral therapy among HIV-positive patients.
Chen GJ; Sun HY; Chang SY; Cheng A; Huang YS; Lin KY; Huang YC; Su YC; Liu WC; Hung CC
Int J Antimicrob Agents; 2019 Jul; 54(1):35-42. PubMed ID: 30905695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
